On April 19, 2021, Abeona Therapeutics Inc. filed a Current Report on Form 8-K disclosing under Item 5.02 that Leila Alland, M.D. and Donald Wuchterl were appointed to serve on the Board of Directors (the “Board”) of the Company effective on April 14, 2021. At the time of this filing, Dr. Alland and Mr. Wuchterl had not been appointed to serve on any committees of the Board. Pursuant to Instruction (2) to Item 5.02 of Form 8-K, the Company is filing this amendment to its prior Current Report on Form 8-K for the sole purpose of disclosing that (i) Dr. Alland will serve as a member of the Board’s Compensation Committee and its Nominating and Corporate Governance Committee and (ii) Mr. Wuchterl will serve as a member of the Board’s Nominating and Corporate Governance Committee. The committee appointments became effective as of May 24, 2021.